207 related articles for article (PubMed ID: 12912944)
1. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Topalian SL; Sherry RM; Restifo NP; Wunderlich JR; Seipp CA; Rogers-Freezer L; Morton KE; Mavroukakis SA; Gritz L; Panicali DL; White DE
Clin Cancer Res; 2003 Aug; 9(8):2973-80. PubMed ID: 12912944
[TBL] [Abstract][Full Text] [Related]
2. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
Phan GQ; Touloukian CE; Yang JC; Restifo NP; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE; Rosenberg SA
J Immunother; 2003; 26(4):349-56. PubMed ID: 12843797
[TBL] [Abstract][Full Text] [Related]
3. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
4. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
5. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Nagorsen D; Panelli M; Dudley ME; Finkelstein SE; Rosenberg SA; Marincola FM
Gene Ther; 2003 Sep; 10(20):1754-65. PubMed ID: 12939642
[TBL] [Abstract][Full Text] [Related]
6. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
7. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
Linette GP; Zhang D; Hodi FS; Jonasch EP; Longerich S; Stowell CP; Webb IJ; Daley H; Soiffer RJ; Cheung AM; Eapen SG; Fee SV; Rubin KM; Sober AJ; Haluska FG
Clin Cancer Res; 2005 Nov; 11(21):7692-9. PubMed ID: 16278389
[TBL] [Abstract][Full Text] [Related]
8. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
9. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.
Astsaturov I; Petrella T; Bagriacik EU; de Benedette M; Uger R; Lumber G; Berinstein N; Elias I; Iscoe N; Hammond C; Hamilton P; Spaner DE
Clin Cancer Res; 2003 Oct; 9(12):4347-55. PubMed ID: 14555505
[TBL] [Abstract][Full Text] [Related]
10. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.
Salgaller ML; Marincola FM; Cormier JN; Rosenberg SA
Cancer Res; 1996 Oct; 56(20):4749-57. PubMed ID: 8840994
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
12. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
14. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
Irvine KR; Parkhurst MR; Shulman EP; Tupesis JP; Custer M; Touloukian CE; Robbins PF; Yafal AG; Greenhalgh P; Sutmuller RP; Offringa R; Rosenberg SA; Restifo NP
Cancer Res; 1999 Jun; 59(11):2536-40. PubMed ID: 10363968
[TBL] [Abstract][Full Text] [Related]
15. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
Parkhurst MR; Riley JP; Robbins PF; Rosenberg SA
J Immunother; 2004; 27(2):79-91. PubMed ID: 14770079
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
[TBL] [Abstract][Full Text] [Related]
19. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
[TBL] [Abstract][Full Text] [Related]
20. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
